APVO — Aptevo Therapeutics Share News
0.000.00%
Last trade - 00:00Aptevo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aptevo Therapeutics Says Cash And Cash Equivalents As Of March 31 Totaling $25.3 Mln
Aptevo Therapeutics Inc expected to post a loss of $1.18 a share - Earnings Preview
Brief: Aptevo Therapeutics Raises $9.6 Mln In Non-Dilutive Funding
Brief: Alligator Bioscience & Aptevo Therapeutics Announce Dosing Of First Patient With ALG.APV-527 In Phase 1 Clinical Trial
Brief: Aptevo Therapeutics Files Provisional Patent For Fifth Bispecific Antibody Apvo711, Intended For Treatment Of Solid Tumors
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber
U.S. STOCKS ON THE MOVE-Microsoft, Aptevo, Rivian
Aptevo nearly doubles on positive results from early-stage trial for leukemia drug
Brief: Alligator Bioscience, Aptevo Therapeutics Announce FDA Issues "May Proceed" Notification
Brief: Aptevo Therapeutics Quarterly Diluted EPS $5.58
Brief: Aptevo Therapeutics Announces New Preliminary Remission Data On Four Additional Patients Enrolled In On-Going Apvo436 Dose Expansion Phase 1B Trial
U.S. RESEARCH ROUNDUP-First Solar, Henry Schein, Petiq
Aptevo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aptevo Therapeutics Reports Quarterly Loss Per Share $1.55
Aptevo Therapeutics falls on Nasdaq letter for non-compliance with listing norm
Brief: Aptevo Therapeutics Inc- On April 1, Received A Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule
Brief: Aptevo Announces Monotherapy Patient Got Transplant In APVO436 Expansion Trial